Praxis Precision Medicines

What Praxis Precision Medicines does

Praxis Precision Medicines is a fully integrated, clinical-to-commercial stage CNS precision neuroscience biopharmaceutical company founded in 2015 and headquartered in Boston, Massachusetts, trading on NASDAQ under the ticker PRAX. The company translates insights from human genetic epilepsies into therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, operating two proprietary discovery platforms — Cerebrum (a small molecule platform applying computational and experimental tools to develop orally available precision modulators of neuronal excitability, including T-type calcium channel and sodium channel modulators) and Solidus (an antisense oligonucleotide engine anchored on proprietary computational methodology producing gapmer and splice-switching ASOs). Its pipeline spans movement disorders and epilepsy with four late-stage assets: ulixacaltamide for essential tremor (NDA accepted, PDUFA January 29, 2027), relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (NDA accepted under Priority Review, PDUFA September 27, 2026), vormatrigine for focal onset seizures (Phase 2/3, POWER1 endpoint not met), and elsunersen for early onset SCN2A DEE (Breakthrough Therapy Designation granted June 2026).

Praxis is pre-commercial with zero product revenue as of Q1 2026, operating a capital-intensive clinical development business funded through repeated public equity offerings totaling over $1.6 billion since IPO, with approximately $1.4 billion in cash and investments funding operations into 2028. The go-to-market model upon FDA approval will deploy specialty pharmacy distribution and field sales targeting specialized neurology prescribers and rare disease patients across two simultaneous launches — ulixacaltamide into a large essential tremor patient population of approximately 7 million in the United States, and relutrigine into the ultra-rare SCN2A/SCN8A-DEE population. Management has reinforced commercial readiness through January 2026 leadership restructuring, including the promotion of Megan Sniecinski to Chief Operating Officer and the addition of former Pfizer CEO Jeffrey Kindler and former Vertex COO Stuart Arbuckle to the board.

The company's revenue model is presently non-operational, with future economics dependent on FDA approvals, pricing, and physician adoption across indications with combined peak revenue potential exceeding $20 billion based on analyst and management estimates. Stakeholder value is currently driven by regulatory and clinical milestones — multiple Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from FDA, plus EMA PRIME designation for elsunersen — rather than recurring product sales.

Name

Praxis Precision Medicines

Legal name

Praxis Precision Medicines, Inc.

Website

https://praxismedicines.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

Praxis Precision Medicines is a clinical-stage CNS biopharmaceutical company developing precision small molecule and antisense oligonucleotide therapies for genetic epilepsies and essential tremor, with two NDAs under FDA review and combined peak revenue potential exceeding $20 billion.

Ownership category

akta.pro rank

Product category

CNS Therapeutics / Precision Neuroscience Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Precision neuroscience
• CNS therapeutics
• Antisense oligonucleotide therapy
• Epilepsy treatment drugs
• Ion channel modulators

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Pre-commercial stage biopharmaceutical company with no current revenue. Planning to launch multiple CNS therapies pending FDA approvals for ulixacaltamide (essential tremor) and relutrigine (DEEs). Four late-stage clinical assets carry projected combined revenue potential exceeding $20 billion.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, including essential tremor, developmental and epileptic encephalopathies, focal onset seizures, and generalized epilepsy. The company leverages two proprietary discovery platforms: Cerebrum (small molecule platform for orally available neuronal excitability modulators) and Solidus (antisense oligonucleotide discovery engine). Late-stage drug candidates include ulixacaltamide for essential tremor, relutrigine for SCN2A/SCN8A-DEEs, vormatrigine for focal epilepsy, and elsunersen for SCN2A-DEE.

Product overview

Praxis Precision Medicines is a fully integrated CNS precision neuroscience biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company operates two dedicated technology platforms: Cerebrum (small molecule platform) and Solidus (antisense oligonucleotide platform). The portfolio spans movement disorders and epilepsy, including ulixacaltamide for essential tremor (Phase 3 complete, NDA accepted with January 2027 PDUFA), relutrigine for SCN2A/8A DEEs (Phase 2/3, NDA accepted with September 2026 PDUFA under Priority Review), vormatrigine for focal onset seizures (Phase 2/3), and elsunersen for early onset SCN2A DEE (Phase 1/2). Multiple candidates have received Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from FDA and EMA.

Differentiator

Problem solved

Functional benefit

Products and services

• Ulixacaltamide Selective T-type calcium channel modulator in development as an oral precision therapy for essential tremor in adults; received FDA Breakthrough Therapy Designation and NDA acceptance with PDUFA target action date of January 29, 2027.
• Relutrigine Sodium channel functional state modulator for SCN2A- and SCN8A-DEEs and broad developmental and epileptic encephalopathies; received FDA Breakthrough Therapy Designation, Orphan Drug Designation, and Priority Review with PDUFA target action date September 27, 2026.
• Vormatrigine Sodium channel functional state modulator for focal onset seizures and generalized epilepsy; being evaluated in POWER1 and POWER2 Phase 2/3 trials.
• Elsunersen (PRAX-222) Gapmer antisense oligonucleotide for early onset SCN2A developmental and epileptic encephalopathy; received FDA Orphan Drug Designation, Rare Pediatric Disease Designation, and Breakthrough Therapy Designation, plus EMA Orphan Drug Designation and Priority Medicines (PRIME) designation.
• PRAX-020 KCNT1 specific inhibitor small molecule for KCNT1-related conditions including genetic epilepsies.
• PRAX-080 Gapmer antisense oligonucleotide for PCDH19-related conditions.
• PRAX-090 Splice switching antisense oligonucleotide for SYNGAP1-related conditions.
• PRAX-100 Antisense oligonucleotide for SCN2A Autism with undisclosed mechanism.
• PRAX-050 Movement disorders program with undisclosed mechanism.

Quantifiable outcome

• 77% sham-adjusted reduction in monthly seizures among pediatric SCN2A-DEE patients (EMBRAVE Part A trial)
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• SEQSTERcoreTechnology or Integration · 2 February 2026Expanded partnership with SEQSTER to accelerate clinical trials and data collection in CNS disorders. The collaboration builds on early success in Praxis's Essential3 Program for Essential Tremor, utilizing SEQSTER's 1-Click DataLake technology to expedite CNS disorder trials.
• SK pharmtecominorOthersPraxis Precision Medicines participated as a speaker and panelist at SK pharmteco's Innovations in Pharmaceutical Manufacturing symposium in Cambridge, Massachusetts, discussing topics including synthetic biology, yeast metabolic engineering, small-molecule scale-up, and stereochemical control.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sage Therapeutics: Clinical-stage CNS biopharmaceutical company developing therapies for neurological and psychiatric disorders. Most comparable to Praxis given its focus on CNS innovation, late-stage CNS pipeline, and similar pre-commercial profile with a breakthrough-designated asset.
• Marinus Pharmaceuticals: Specializes in therapeutics for rare seizure disorders, including a recently approved product for CDKL5 deficiency disorder. Directly comparable to Praxis's SCN2A/SCN8A DEE franchise given its rare pediatric epilepsy focus and similar regulatory pathway strategy.
• PTC Therapeutics: Rare disease biopharmaceutical company with multiple approved products and a CNS franchise. Highly comparable given shared leadership pedigree (Marcio Souza was previously COO), rare disease commercial infrastructure, and small-molecule platform approach.
• Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotide medicines for genetic diseases, including SCN1A-related Dravet syndrome. Directly comparable given shared focus on ion channelopathies and the Solidus ASO platform approach to CNS genetic epilepsies.

Broad incumbents

• UCB: Global biopharmaceutical company with a major CNS and epilepsy franchise including multiple approved anti-seizure medications. Comparable as a broad incumbent in the CNS/epilepsy space that Praxis's relutrigine and vormatrigine will compete against commercially.
• Jazz Pharmaceuticals: Specialty biopharmaceutical company with a significant CNS/epilepsy portfolio including recently acquired products for rare epilepsies. Comparable given its specialty pharma commercial model focused on CNS and rare neurological disorders.
• Biogen: Major CNS-focused biopharmaceutical company with a portfolio spanning neurology, rare disease, and movement disorders. Comparable as a broad incumbent in CNS with similar strategic emphasis on neurological disease modification.
• Ionis Pharmaceuticals: Established leader in antisense oligonucleotide drug discovery and development with multiple approved products. Comparable as a broader incumbent in the ASO modality that Praxis's Solidus platform competes with in CNS indications.

Emerging players

• BridgeBio Pharma: Clinical-stage genetic disease company with programs across rare disorders. Comparable given its genetically driven drug development approach targeting defined patient populations, similar to Praxis's genetic epilepsy strategy.
• Wave Life Sciences: Clinical-stage genetic medicines company developing oligonucleotide therapies, including programs for CNS disorders such as SCN2A. Directly comparable as an emerging ASO player targeting overlapping CNS genetic epilepsies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/praxis-precision-medicines
• Xx.com/PraxisMedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds8 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Praxis Precision Medicines